AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02166229
Drug: Divalproex sodium
RxNorm normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00522574
Drug: XL019
RxNorm normalized name: XL019
DrugBank: XL019 (DB05243)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gelatin capsules supplied in 5-mg, 25-mg, and 100-mg strengths
Trial: NCT04712266
Drug: Glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: calculated IV insulin:Glucagon molar ratio
Trial: NCT04712266
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: calculated IV Insulin dose infused at a constant rate
Trial: NCT00505102
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: cyclosporine dose reduced of 50% after introduction of everolimus
Trial: NCT01565590
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.2-1.5 mcg/kg/hr
Trial: NCT01565590
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-80 mcg/kg/min
Trial: NCT01599702
Drug: Iron Isomaltoside 1000
RxNorm normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500-3000mg IV depending on HB level, sex and body weight
Trial: NCT00170742
Drug: Octreotide, 30 mg i.m. LAR formulation
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01669642
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: participants who need ketamine sedation for abscess drainage or fracture reduction will be approached for enrollment. there is no comparison group. A predetermined dose of Ketamine will be administered over 5 seconds or less intravenously. Sedation provider will assess for effectiveness of sedation at one minute.
Trial: NCT02031432
Drug: Cebranopadol
RxNorm normalized name: Cebranopadol
DrugBank: Cebranopadol (DB12830)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet; strengths: 200, 400, or 600 µg
Trial: NCT00753688
Drug: PAZOPANIB
RxNorm normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 800 mg once daily orally
Trial: NCT00442767
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy was continued as per prescribed home regimen without pramlintide. Subjects self-administered a rapid-acting insulin analog (aspart or lispro) bolus based on their individual insulin: carbohydrate ratio, before meal.
Trial: NCT00442767
Drug: Pramlintide + Insulin
DrugBank: Pramlintide (DB01278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30mcg of pramlintide was administered subcutaneously immediately prior to the meal and insulin was given 15 minutes after the meal. The dose of insulin was reduced by 20%.
Trial: NCT01183312
Drug: Flumazenil
RxNorm normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual flumazenil
Trial: NCT02103881
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg of intramuscular ketamine for severe pre-hospital agitation
Trial: NCT02103881
Drug: Haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol 10 mg intramuscular for severe prehospital agitation.
Trial: NCT00702910
Drug: Magnesium Stearate
RxNorm normalized name: Magnesium stearate
DrugBank: Magnesium stearate (DB14077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium Stearate
Trial: NCT00685841
Drug: Arformoterol tartrate inhalation solution
RxNorm normalized name: ARFORMOTEROL TARTRATE 15 ug in 2 mL RESPIRATORY (INHALATION) SOLUTION [Arformoterol Tartrate Inhalation Solution]
DrugBank: Arformoterol (DB01274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arformoterol 50 mcg QD
Trial: NCT00685841
Drug: Arformoterol tartrate inhalation solution
RxNorm normalized name: ARFORMOTEROL TARTRATE 15 ug in 2 mL RESPIRATORY (INHALATION) SOLUTION [Arformoterol Tartrate Inhalation Solution]
DrugBank: Arformoterol (DB01274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arformoterol 25 mcg BID
Trial: NCT00685841
Drug: Arformoterol tartrate inhalation solution
RxNorm normalized name: ARFORMOTEROL TARTRATE 15 ug in 2 mL RESPIRATORY (INHALATION) SOLUTION [Arformoterol Tartrate Inhalation Solution]
DrugBank: Arformoterol (DB01274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arformoterol 15 mcg BID
Trial: NCT00685841
Drug: Salmeterol MDI
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Salmeterol MDI 42 mcg BID
Trial: NCT00387335
Drug: sunitinib malate
RxNorm normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given orally
Trial: NCT00004685
Drug: albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03870685
Drug: Exparel
RxNorm normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: liposomal bupivacaine
Trial: NCT05918588
Drug: Belumosudil mesylate
RxNorm normalized name: Belumosudil Mesylate
DrugBank: Belumosudil (DB16703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: capsule; Route of administration: oral
Trial: NCT02598635
Drug: Cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients on peritoneal dialysis and 25-(OH) levels \<20 ng/mL will received one capsule of cholecalciferol (4800 U) once a day for 16 weeks.
Trial: NCT04882813
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin dispensing claim is used as the exposure group.
Trial: NCT04882813
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin dispensing claim is used as the reference group.
Trial: NCT05606055
Drug: BIC/FTC/TAF: Bictegravir/emtricitabina/tenofovir alafenamida fumarato
DrugBank: Bictegravir (DB11799)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: This is a study to assess the impact of immediate ART (FAST ART or SDT) against conventional treatment (CT) on the time to reach an undetectable HIV-1 viral load.
Trial: NCT01593228
Drug: Iniparib (SAR240550/BSI-201)
RxNorm normalized name: Iniparib
DrugBank: Iniparib (DB13877)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Solution~Route of administration: Intravenous
Trial: NCT01593228
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form:Solution~Route of administration: Intravenous
Trial: NCT01593228
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form:Solution~Route of administration: Intravenous
Trial: NCT01593228
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form:Solution~Route of administration: Intravenous
Trial: NCT01593228
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form:Solution~Route of administration: Intravenous
Trial: NCT01593228
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Solution~Route of administration: Intravenous
Trial: NCT04169854
Drug: Lidocaine 5% patch
RxNorm normalized name: LIDOCAINE 5% PATCH
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The Lidocaine 5% Patch will be applied to cover the marked incision site and head-holders sites for 3 consecutive preoperative days between 6:00 P.M. to 6:00 A.M.. Research assistants will be responsible for instructing patients to cover the patches correctly.
Trial: NCT02013128
Drug: Ublituximab
RxNorm normalized name: Ublituximab
DrugBank: Ublituximab (DB11850)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ublituximab (IV infusion)
Trial: NCT02013128
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib oral daily dose
Trial: NCT03321318
Drug: Bazedoxifene 20 mg
RxNorm normalized name: bazedoxifene 20 MG
DrugBank: Bazedoxifene (DB06401)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Investigational product is prescribed to all of randomized subjects
Trial: NCT03321318
Drug: Cholecalciferol 800IU
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational product is prescribed to all of randomized subjects
Trial: NCT02628613
Drug: Vinorelbine plus Epirubicin
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Evaluate the efficiency and safety of vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations
Trial: NCT02628613
Drug: Paclitaxel plus Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: standard neoadjuvant chemotherapy
Trial: NCT00840918
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Lidocaine Group - Lidocaine administered intravenously throughout surgery and during the 24 hours following surgery.
Trial: NCT01029418
Drug: AZD6244 and sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dose escalation of AZD6244; sorafenib 400mg bd
Trial: NCT00607737
Drug: insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3 cutaneous injections
Trial: NCT00607737
Drug: saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 cutaneous injections
Trial: NCT03198351
Drug: Teriflunomide (HMR1726)
RxNorm normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Trial: NCT01389609
Drug: Doxazosin 4 mg Japanese marketed IR tablet
RxNorm normalized name: doxazosin 4 MG
DrugBank: Doxazosin (DB00590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate release tablet, 4 mg, single dose
Trial: NCT01389609
Drug: Doxazosin 4 mg ODT with water
RxNorm normalized name: doxazosin 4 MG
DrugBank: Doxazosin (DB00590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orally-disintegrating Tablet , 4 mg, single dose with water
Trial: NCT01389609
Drug: Doxazosin 4 mg ODT without water
RxNorm normalized name: doxazosin 4 MG
DrugBank: Doxazosin (DB00590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orally-disintegrating Tablet , 4 mg, single dose without water
Trial: NCT00312871
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01540071
Drug: NRX 194204
RxNorm normalized name: NRX-1074
DrugBank: NRX-1074 (DB11784)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRX 194204 is an oblong, soft, gelatin capsule and will be taken once a day
Trial: NCT02211066
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02211066
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00119171
Drug: Ispinesib
RxNorm normalized name: Ispinesib
DrugBank: Ispinesib (DB06188)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02725866
Drug: Paritaprevir/ritonavir/ombitasvir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Co-formulated tablet
Trial: NCT02725866
Drug: Dasabuvir
RxNorm normalized name: Dasabuvir
DrugBank: Dasabuvir (DB09183)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablet
Trial: NCT02725866
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet
Trial: NCT00895453
Drug: itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-months maintenance regimen with monthly single-day itraconazole 200mg twice daily (bid)
Trial: NCT00895453
Drug: lactobacillus gasseri
RxNorm normalized name: Lactobacillus Gasseri
DrugBank: Lactobacillus gasseri (DB16543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus vaginal tablets monthly given through 6 days
Trial: NCT02071069
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 400mg/m2 d1,250mg/m2 every week or 500mg/m2 every 2 weeks
Trial: NCT02071069
Drug: irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 180 mg/m2 IV every 2 weeks
Trial: NCT01183455
Drug: Aralast NP
RxNorm normalized name: Aralast NP
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive IV infusions of Aralast NP (90mg/kg) once a week for 12 weeks.
Trial: NCT05399290
Drug: Doxycycline Hyclate
RxNorm normalized name: Doxycycline Hyclate
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg vs 20 mg doxycycline hyclate BID for 12 weeks
Trial: NCT04072263
Drug: Interferon Alfa 2A
RxNorm normalized name: Pegylated-interferon alfa 2a
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha (IFNα) s.c., may work as a low toxic preconditioning regimens that creates the space required for the infused TIL but that it also supports the TIL by sustaining their persistence and indirectly their function, by upregulation of HLA class I on tumor cells and decreasing the numbers of regulatory T cells.
Trial: NCT02414958
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04072263
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: chemotherapy i.v.
Trial: NCT04072263
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy i.v.
Trial: NCT00064051
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00064051
Drug: triapine
RxNorm normalized name: Triapine
DrugBank: Triapine (DB11940)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00001644
Drug: Indinavir
RxNorm normalized name: Indinavir
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001644
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001644
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00001644
Drug: Nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03351569
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous drip.
Trial: NCT03256071
Drug: Decitabine plus Modified BUCY
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine:20 mg/m²/day on day -14 to -10;~Modified BUCY:~1. Sibling:semustine 250 mg/m²/day on day -9;cytarabine 2 g/m²/day on day -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~2. Unrelated:semustine 250 mg/m²/day on day -10;cytarabine 2 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~3. Haploidentical:semustine 250 mg/m²/day on day -10;cytarabine 4 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.
Trial: NCT04552431
Drug: Ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin, 500 mg twice daily
Trial: NCT04552431
Drug: Tamsulosin Hydrochloride
RxNorm normalized name: Tamsulosin Hydrochloride
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamsulosin Hydrochloride, 0.4 mg once daily
Trial: NCT04552431
Drug: Tamsulosin Hydrochloride Placebo
RxNorm normalized name: Tamsulosin Hydrochloride
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamsulosin Hydrochloride Placebo (Placebo-TH) one tablet once daily
Trial: NCT01425229
Drug: Bosentan
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Administration of bosentan: 1 x 125 mg p.o. on day 1, 2 x 125 mg p.o. on day 2-14~* Administration of clarithromycin: 2 x 500 mg p.o. on day 11-14
Trial: NCT02289274
Drug: NVP-1203
RxNorm normalized name: NVP
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NVP-1203(eperisone SR + aceclofenac)
Trial: NCT02289274
Drug: Eperisone SR tab. + and Airtal tab.
DrugBank: Eperisone (DB08992)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eperisone SR and aceclofenac
Trial: NCT03118076
Drug: 0.3% ropivacaine and 50 μg dexmedetomidine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nerve blocks were administered with 0.3% ropivacaine and 50 μg dexmedetomidine.
Trial: NCT03118076
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nerve blocks were administered with 0.3% ropivacaine.
Trial: NCT02436733
Drug: Pemetrexed/Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On day 1 of each cycle, pemetrexed 500 mg/m2 should be administered as IV infusion followed by cisplatin 75 mg/m2 as IV.
Trial: NCT00003775
Drug: leflunomide
RxNorm normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02634827
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02634827
Drug: Midostaurin
RxNorm normalized name: Midostaurin
DrugBank: Midostaurin (DB06595)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT01410799
Drug: Growth Hormone Releasing Hormone (GHRH )
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 PM, 1:00 AM, 3:00 AM, and 5:00 AM for 12 weeks
Trial: NCT01312324
Drug: neoadjuvant docetaxel/cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 cycles of docetaxel plus cisplatin docetaxel 75mg/m2 D1 cisplatin 75mg/m2 D1 every 3 weeks
Trial: NCT01319019
Drug: Salmeterol
RxNorm normalized name: Salmeterol
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Positive control
Trial: NCT00191737
Drug: Atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03926338
Drug: Cohort 1: Neoadjuvant treatment with toripalimab monotherapy for 3 months
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 3 months) followed by surgical resection.
Trial: NCT03926338
Drug: Cohort 2: Neoadjuvant treatment with toripalimab monotherapy for 6 months
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 6 months) followed by surgical resection.
Trial: NCT03936270
Drug: Palbociclib 125mg
RxNorm normalized name: PALBOCICLIB 125MG TAB
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The Palbociclib capsules supplied for this study contains 75 mg, 100 mg or 125 mg of Palbociclib. It must be taken orally 125 mg once daily for 21 consecutive days followed by 7 days off treatment (Schedule 3/1) to comprise a complete cycle of 28 days.
Trial: NCT03936270
Drug: Letrozole 2.5mg
RxNorm normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole will be supplied as a 2.5 mg film-coated tablet. It must be taken at the recommended dose of 2.5 mg once daily.
Trial: NCT04167137
Drug: SYNB1891
RxNorm normalized name: SYNB1891
DrugBank: SYNB1891 (DB17541)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYNB1891 was administered as an IT injection over a dose range of 1 x 10\^6 to 3 x 10\^8 live cells in Arm 1 and 1 x 10\^7 to 3 x 10\^7 in Arm 2.
Trial: NCT04282070
Drug: SHR-1701
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive an intravenous infusion of SHR-1701 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
Trial: NCT04282070
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Maximum 6 cycles for combined therapy.
Trial: NCT04282070
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maximum 6 cycles for combined therapy.